Targeted Trans-splicing Using CRISPR-Cas Systems
This technology provides a novel method of targeting ribonucleic acids for trans-splicing using any CRISPR/Cas13 orthologs having two Higher Eukaryotes and Prokaryotes Nucleotide-binding (HEPN) endonuclease domains (Type VI CRISPR effectors). The method uses the principles of endogenous RNA processing and RNA-writing using a CRISPR/Cas13 protein to initiate the targeted trans-splicing of defective pre-mRNAs, effectively correcting mutations at the pre-translation level in the nucleus and allowing for the treatment of essentially all types of mongenic diseases. The system is a significant improvement over CRISPR-mediated genomic DNA editing and other gene therapies as it allows for the option of transient RNA repair while improving both the specificity and the efficiency of trans-splicing events.
Researchers
-
targeted trans-splicing using crispr/cas13
United States of America | Granted | 11,767,528 -
targeted trans-splicing using crispr/cas13
Australia | Pending -
targeted trans-splicing using crispr/cas13
Canada | Published application -
targeted trans-splicing using crispr/cas13
China | Published application -
targeted trans-splicing using crispr/cas13
European Patent Convention | Published application -
targeted trans-splicing using crispr/cas13
Japan | Published application -
targeted trans-splicing using crispr/cas13
Korea (south) | Published application -
targeted trans-splicing using crispr/cas13
United States of America | Published application
Technology
The CRISPR/Cas13 system (a complex of the nuclease-inactive Cas13, guide RNA, and a repair splice donor/acceptor template), specifically recognizes target sequences on the defective pre-mRNA. The system then mediates the process of trans-splicing, utilizing the repair template to join exons within the pre-mRNA or replace targeted exons. This precise modification ensures the desired edits within the repair template are incorporated into the final mRNA. As a result, a modified RNA molecule is produced, which can encode the corrected protein, a novel protein or serve as therapeutic noncoding or regulatory RNA.
Problem Addressed
This technology addresses the limitations of traditional RNA splicing methods by improving the efficiency and specificity of trans-splicing. It offers a mechanism to precisely repair RNA, increasing protein diversity without altering the genomic DNA. Additionally, it can be exploited for molecular therapy to correct mutated gene products and treat a wide range of diseases.
Advantages
- The use of Cas13 and guide RNA allows for precise manipulation of RNA transcripts
- Enables exon swapping at 5’/3’ ends and internally, in dividing and post-mitotic cells
- Trans-splicing at the pre-mRNA level does not cause changes to genomic DNA
- Potential for one off-the-shelf therapeutic formulation to be able to correct multiple different disease-causing mutations in a gene across a patient population
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.